Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.

By Philip D. Harvey, R. Keefe. American Journal of Psychiatry, 2001

637 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Psychiatry and Mental health, Philosophy

View Paper: https://www.semanticscholar.org/paper/de9e6e48a9d694ddaf91ea93f05611f83ff6cecc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. Michael F. Green
2. J. Cohen
3. Deanna M. Barch
4. R. Heaton
5. Daniel R. Weinberger
6. R. Kern
7. R. Keefe
8. Stephen V. Faraone

In Psychiatry and Mental health

1. Michael F. Green
2. R. Keefe
3. Daniel R. Weinberger
4. R. Heaton
5. R. Kern
6. Larry J. Seidman
7. R. Mesholam-Gately
8. Stephen V. Faraone

In Philosophy

1. Philip D. Harvey
2. Daniel R. Weinberger
3. J. Cohen
4. Terry E. Goldberg
5. S. Marder
6. Susan M. Shortreed
7. Erica E. Moodie

Citations in the corpus

• Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. (2007, methodology): “The neurocognitive tests were chosen by a group of advisors based on published standards, including sensitivity to impairment in schizophrenia, relation to functional outcome, potential sensitivity to treatment, and practicality for a large multisite schizophrenia antipsychotic clinical trial.(52,58”
• Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. (2004, background): “One is that newer antipsychotic medications have cognitive benefits when compared with conventional antipsychotic medications (Harvey and Keefe 2001; Keefe et al 1999; Meltzer and McGurk 1999).”
• A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. (2005, neutral): “Similar to other meta-analyses of cognition in schizophrenia (Harvey and Keefe, 2001 ; Heinrichs and Zakzanis, 1998) effect sizes were calculated for individual neuropsychological tests, although in several cases highly similar tests were combined into a single measure (e.g. verbal list learning).”
• Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. (2004, background): “Indeed, improvements in cognition [ 53 ] and in fMRI response patterns have been reported in patients treated with these new agents [54].”
• Cognitive deficits and functional outcome in schizophrenia (2006, background): “A review by Harvey and Keefe (2001) noted several methodological shortcomings and calculated only modest effect sizes for improvements across atypical multiple antipsychotic medications and cognitive domains.”
• Neurocognition in first-episode schizophrenia: a meta-analytic review. (2009, result): “…often explicitly tested the effects of antipsychotic medications or attempted to study persons in a medicationfree state, it can be inferred that these medications tended to have some small, aggregate positive effect on neurocognition in FE schizophrenia, consistent with Harvey and Keefe (2001).”